sulfonylurea vs glp 1 GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 receptor agonist versus DPP-4
Description
What began as treatments for diabetes and obesity has rapidly expanded into prevention of cardiovascular disease, slowing kidney decline, tackling liver disease, and even tentative explorations into neurodegeneration
In other words, GLP-1s can help people create the energy deficit that is necessary to lose weight
Challenges: Responding to a Market That Wont Wait The rapid rise of GLP-1s has introduced significant operational and strategic challenges across the pharmaceutical manufacturing landscape
Figure 3 summarizes the main advantages and disadvantages of GLP-1 RA prescription
Around 40% of Americans ages 20 and older are considered obese, and nearly 10% are severely obese
